, Volume 17, Issue 3, pp 151–161 | Cite as

Analgesic targets: today and tomorrow

  • Ian W. RodgerEmail author


Pain is recognized as a multifactorial sensory experience that is wholly unpleasant. It can vary in intensity from mild to severe and its duration can be anything from transient to persistent. Today we know so much more about the peripheral nociceptor as the primary detection apparatus for painful stimuli. We also understand in far greater detail the neurochemical mechanisms that occur at the level of the spinal cord and the complex interplay that exists between excitatory and inhibitory neural pathways. As a consequence of the assembly of this new body of evidence there are clear pointers that direct our attention to receptors, signaling pathways, enzymes and ion channels that all have the potential to be targets for novel, effective analgesics. The purpose of this review is to highlight some of the knowledge that has been assembled on this subject in recent years.


Pain Nociceptor Neuromodulation Spinal cord Analgesic targets 


  1. Agarwal N, Pacher P, Tegeder I, et al. Cannabinoid mediated analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci. 2007;7:870–9.CrossRefGoogle Scholar
  2. Ahmadi S, Lippross S, Neuhuber WL, et al. PGE2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci. 2002;5:34–40.PubMedCrossRefGoogle Scholar
  3. Akopian AN, Sivilotti L, Wood JN, et al. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379:257–62.PubMedCrossRefGoogle Scholar
  4. Blair NT, Bean BP. Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na+ current, and Ca2+ current in the action potentials of nociceptive sensory neurons. J Neurosci. 2002;22:10277–90.PubMedGoogle Scholar
  5. Bley KR. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs. 2004;13:1445–56.PubMedCrossRefGoogle Scholar
  6. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist icatibant. J Allergy Clin Immunol. 2007;119:1497–503.PubMedCrossRefGoogle Scholar
  7. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–102.PubMedCrossRefGoogle Scholar
  8. Brose WG, Gutlove DP, Luther RR, et al. Use of intrathecal SNX-111, a novel N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain. 1997;13:256–9.PubMedCrossRefGoogle Scholar
  9. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816–24.PubMedCrossRefGoogle Scholar
  10. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521–5.PubMedCrossRefGoogle Scholar
  11. Chizh BA, O’Donnell MB, Napoltano A, et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain. 2007;132:132–41.PubMedCrossRefGoogle Scholar
  12. Chuang H, Prescott ED, Kong H, et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4, 5)P2-mediated inhibition. Nature. 2001;411:957–62.PubMedCrossRefGoogle Scholar
  13. Cockayne DA, Hamilton SG, Zhu Q-M, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407:1011–5.PubMedCrossRefGoogle Scholar
  14. Coggeshall RE, Tate S, Carlton SM, et al. Differential expression of tetrodotoxin-resistant sodium channels Nav1.8 and Nav1.9 in normal and inflamed rats. Neurosci Lett. 2004;355:45–8.PubMedCrossRefGoogle Scholar
  15. Coull JAM, Beggs S, Boudreau D, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438:1017–21.PubMedCrossRefGoogle Scholar
  16. Dray A. Neuropathic pain: emerging treatments. Br J Anaesth. 2008;101:48–58.PubMedCrossRefGoogle Scholar
  17. Feletou M, Germain M, Thurieau C, et al. Agonistic and antagonistic properties of the bradykinin B2 receptor antagonist, Hoe 140, in isolated blood vessels from different species. Br J Pharmacol. 1994;112:683–9.PubMedGoogle Scholar
  18. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cycloxygenase-2. N Engl J Med. 2001;345:433–42.PubMedCrossRefGoogle Scholar
  19. Fox A, Bevan S. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs. 2005;14:695–703.PubMedCrossRefGoogle Scholar
  20. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871–4.PubMedCrossRefGoogle Scholar
  21. Gogas KR. Glutamate therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol. 2006;6:68–74.PubMedCrossRefGoogle Scholar
  22. Gold MS, Weinreich D, Kim CS, et al. Redistribution of Na(V)1.8 in uninjured axons enables neuropathic pain. J Neurosci. 2003;23:158–66.PubMedGoogle Scholar
  23. Goldin AL. Resurgence of sodium channel research. Annu Rev Physiol. 2001;63:871–94.PubMedCrossRefGoogle Scholar
  24. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4–15.PubMedCrossRefGoogle Scholar
  25. Harvey RJ, Depner UB, Wassle H, et al. Glyα3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science. 2004;304:884–7.PubMedCrossRefGoogle Scholar
  26. Jarvis MF, Honore P, Shieh C-C, et al. A-803467, a potent and selective Nav1, 8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA. 2007;104:8520–5.PubMedCrossRefGoogle Scholar
  27. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413:203–10.PubMedCrossRefGoogle Scholar
  28. Kang M-G, Felix R, Campbell KP, et al. Long term regulation of voltage-gated Ca2+ channels by gabapentin. FEBS Lett. 2002;528:177–82.PubMedCrossRefGoogle Scholar
  29. Kim C, Jun K, Lee T, et al. Altered nociceptive responses in mice deficient in the α1δ subunit of the voltage-dependent calcium channel. Mol Cell Neurosci. 2001;18:235–45.PubMedCrossRefGoogle Scholar
  30. Knabl J, Witschi R, Hosl K, et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature. 2008;451:330–4.PubMedCrossRefGoogle Scholar
  31. Lane N, Webster L, Shiao-Ping L, et al. RN624 (anti NGF) improves pain and function in subjects with moderate knee osteoarthritis: a phase I study. Arthritis Rheum. 2005;52:S461.CrossRefGoogle Scholar
  32. Liu XJ, Gingrich JR, Vargas-Caballero M, et al. Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nature. 2008;14:1325–32.CrossRefGoogle Scholar
  33. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001;21:1868–75.PubMedGoogle Scholar
  34. Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific channel α2δ-1 subunit upregulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002;303:1199–205.PubMedCrossRefGoogle Scholar
  35. McGaraughty S, Jarvis MF. Antinociceptive properties of a non-nucleotide P2X3/P2X2/3 receptor antagonist. Drug News Perspect. 2005;18:501–7.PubMedCrossRefGoogle Scholar
  36. McGuire D, Bowersox S, Fellmann JD, et al. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol. 1997;30:400–3.PubMedCrossRefGoogle Scholar
  37. Merskey H, Bogduk N. Classification of chronic pain. Seattle: IASP Press; 1994. p. 210.Google Scholar
  38. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006;5:75–85.PubMedCrossRefGoogle Scholar
  39. Moore KA, Kohno T, Karchewski LA, et al. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci. 2002;22:6724–31.PubMedGoogle Scholar
  40. Nurmikko TJ, Serpell MG, Hoggat B, et al. Savitex successfully treats neuropathic pain characterized by allodynia: a randomized, double blind, placebo-controlled clinical trial. Pain. 2007;133:210–20.PubMedCrossRefGoogle Scholar
  41. Owolabi JB, Rizkalla G, Tehim A, et al. Characterization of anti-allodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharmacol Exp Ther. 1999;289:1271–6.PubMedGoogle Scholar
  42. Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov. 2009;8:55–68.PubMedCrossRefGoogle Scholar
  43. Ramer MS, Bradbury EJ, McMahon SB, et al. Nerve growth factor induces P2X(3) expression in sensory neurons. J Neurochem. 2001;77:864–75.PubMedCrossRefGoogle Scholar
  44. Reinold H, Ahmadi S, Depner UB, et al. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest. 2005;115:673–9.PubMedGoogle Scholar
  45. Riendeau D, Aspiotis R, Ethier D, et al. Inhibitors of the inducible microsomal prostaglandin E2 synthase (MPGES-1) derived from MK-886. Biorg Med Chem Lett. 2005;15:3352–5.CrossRefGoogle Scholar
  46. Samad TA, Sapirstein A, Woolf CJ, et al. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med. 2002;8:390–6.PubMedCrossRefGoogle Scholar
  47. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10:1361–8.PubMedCrossRefGoogle Scholar
  48. Sharp CJ, Reeve AJ, Collins SD, et al. Investigation into the role of P2X3/P2X2/3 receptors in neuropathic pain following chronic constriction injury in the rat: an electrophysiology study. Br J Pharmacol. 2006;148:845–52.PubMedCrossRefGoogle Scholar
  49. Sherrington CS. The integrative action of the nervous system. New York: Scribner; 1906.Google Scholar
  50. Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx. 2005;4:662–70.CrossRefGoogle Scholar
  51. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63–70.PubMedCrossRefGoogle Scholar
  52. Szallasi A, Cortright DN, Blum CA, et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev. 2007;6:357–72.CrossRefGoogle Scholar
  53. Tanaka M, Cummins TR, Ishikawa K, et al. SNS sodium channel expression increases in dorsal root ganglion neurons in the carrageenan inflammatory pain model. Neuroreport. 1998;9:967–72.PubMedCrossRefGoogle Scholar
  54. Torsney C, MacDermott AB. A painful factor. Nature. 2005;438:923–5.PubMedCrossRefGoogle Scholar
  55. Tsuda M, Shigemoto-Mogami Y, Koizumi S, et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003;424:778–83.PubMedCrossRefGoogle Scholar
  56. Vega-Hernandez A, Felix R. Down-regulation of N-type-activated Ca2+ channels by gabapentin. Cell Mol Neurobiol. 2002;22:185–90.PubMedCrossRefGoogle Scholar
  57. Vellani V, Zachrisson O, McNaughton PA. Functional bradykinin B1 receptors are expressed in nociceptive neurones and are upregulated by the neurotrophin GDNF. J Physiol. 2004;560:391–401.PubMedCrossRefGoogle Scholar
  58. Wang H, Woolf CJ. Pain TRPs. Neuron. 2005;46:9–12.PubMedCrossRefGoogle Scholar
  59. Wang H, Kohno T, Amaya F, et al. Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic transmission. J Neurosci. 2005;25:7986–92.PubMedCrossRefGoogle Scholar
  60. Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet. 2008;371:270–3.PubMedCrossRefGoogle Scholar
  61. Winquist RJ, Pan JQ, Gribkoff VK. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochem Pharmacol. 2005;70(48):9–499.Google Scholar
  62. Wirth K, Hock FJ, Albus U, et al. Hoe 140, a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991;102:774–7.PubMedGoogle Scholar
  63. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140:441–51.PubMedGoogle Scholar
  64. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765–8.PubMedCrossRefGoogle Scholar
  65. Zeilhofer HU. The glycinergic control of spinal pain. Cell Mol Life Sci. 2005;62:2027–35.PubMedCrossRefGoogle Scholar
  66. Zeilhofer HU, Brune K. Analgesic strategies beyond the inhibition of cyclooxygenases. Trends Pharmacol Sci. 2006;9:467–74.CrossRefGoogle Scholar
  67. Zimmermann K, Leffler A, Babes A, et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature. 2007;447(85):5–859.Google Scholar

Copyright information

© Birkhäuser Verlag, Basel/Switzerland 2009

Authors and Affiliations

  1. 1.St Joseph’s Healthcare Hamilton, Department of Medicine, Faculty of Health SciencesMcMaster UniversityHamiltonCanada

Personalised recommendations